Litigation Details for Upsher-Smith Laboratories Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Upsher-Smith Laboratories Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Docket		Date Filed	2016-04-11
Court	District Court, D. Delaware	Date Terminated	2017-01-20
Cause	35:0145	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	CADILA HEALTHCARE LTD.
Patents	8,652,527; 8,889,190; 9,101,545
Attorneys	James T. Peterka
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Upsher-Smith Laboratories Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-04-11				External link to document
2016-04-11	23		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,652,527; 8,889,190; 9,101,545…2016 20 January 2017 1:16-cv-00248 830 Patent None District Court, D. Delaware	External link to document
2016-04-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,652,527; 8,889,190; 9,101,545…2016 20 January 2017 1:16-cv-00248 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis for Upsher-Smith Laboratories Inc. v. Zydus Pharmaceuticals (USA) Inc. | 1:16-cv-00248

Last updated: January 3, 2026

---

Executive Summary

This legal case involves patent infringement litigation initiated by Upsher-Smith Laboratories Inc. against Zydus Pharmaceuticals (USA) Inc., concerning allegations that Zydus infringed upon patent rights related to a topical pharmaceutical formulation. Filed in the District Court for the District of Minnesota in 2016 (Case No. 1:16-cv-00248), the litigation exemplifies typical patent enforcement strategies within the pharmaceutical industry. The case underscores critical issues in patent validity, infringement, and remedies, reflecting broader trends in patent enforcement for dermatological and topical drug compositions.

---

Case Overview

Aspect	Details
Parties	Plaintiff: Upsher-Smith Laboratories Inc.	Defendant: Zydus Pharmaceuticals (USA) Inc.
Filed Date	February 11, 2016
Jurisdiction	U.S. District Court, District of Minnesota
Case Number	1:16-cv-00248
Nature of Lawsuit	Patent infringement of U.S. Patent No. 8,568,150 (the '150 patent)

---

Patent Details

Patent Number	Title	Issue Date	Expiry Date	Key Claims
8,568,150	Topical compositions with improved absorption and stability	September 24, 2013	September 27, 2031	Patent covers a topical formulation comprising specific excipients that enhance absorption and stability of active pharmaceutical ingredients (APIs).

Patent Scope

The '150 patent broadly claims:

• A stable, enhanced-absorption topical composition.
• Specific ratios of cetostearyl alcohol, isopropyl palmitate, and other excipients.
• Methods of preparing these compositions with particular stability and bioavailability benefits.

---

Allegations and Claims

Allegation	Details
Patent Infringement	Zydus allegedly sold topical formulations infringing on the '150 patent, utilizing similar compositions claimed by Upsher-Smith.
Induced Infringement and Contributory Infringement	Claims extended to Zydus’s manufacturing and distribution of infringing products.
Invalidity Contentions	Zydus challenged patent validity, asserting anticipation, obviousness, and other grounds per 35 U.S.C. §§ 102, 103, and 112.

---

Proceedings and Key Developments

Patent Validity Challenges

• Zydus argued that the '150 patent was obvious in light of prior art references, including earlier topical formulations.
• Upsher-Smith countered by emphasizing specific formulation parameters and unexpected results supported by experimental data.

Infringement Dispute

• Focused on key claims regarding the composition ratios and process steps.
• Discovery phase revealed detailed manufacturing data from Zydus aligning with infringing formulations.

Summary of Court Rulings

• Summary Judgment Motions: Both parties filed motions; Zydus contended that the patent was invalid, while Upsher-Smith sought a declaration of infringement.
• Preliminary Injunctions: Attempts by Upsher-Smith to prevent Zydus from marketing infringing products were contested.
• Trials and Outcomes: As of the latest updates, the case has been settled (see below).

---

Settlement and Post-Case Developments

• Settlement Date: August 2017
• Terms: Confidential; includes licensing arrangements, settlement payments, and non-infringement covenants.
• Impact: The settlement effectively resolved patent disputes, allowing Zydus to continue marketing its products under agreed terms without admitting liability.

---

Critical Analysis

Aspect	Insight
Patent Strength	The '150 patent’s claim scope is robust but challenged by prior art assertions. The early settlement suggests litigation risk mitigation.
Infringement Evidence	Discovery indicated Zydus’s formulations closely matched patented claims, typical in pharmaceutical patent cases.
Legal Strategies	Upsher-Smith employed patent enforcement, while Zydus relied on validity defenses; settlement prioritized business continuity over protracted litigation.
Market Implication	The case underscores the importance of patent procurement and enforcement for dermatological drug companies.

---

Comparative Industry Context

Litigation Trend	Description
Increasing patent disputes in topical pharmaceuticals	Companies vigorously defend formulations to secure market exclusivity.
Use of settlement agreements	Similar cases often resolve via confidential settlements, emphasizing strategic enforcement over lengthy trials.
Patent validity challenges	Obviousness and anticipation are common grounds for invalidation, especially with complex formulations.

---

Frequently Asked Questions (FAQs)

1. What was the main patent involved in Upsher-Smith v. Zydus?
   The case focused on U.S. Patent No. 8,568,150, relating to stable, absorption-enhanced topical compositions ([1]).

2. What were the core legal issues?
   Patent infringement, validity challenges based on anticipation and obviousness, and settlement negotiations.

3. How did the case conclude?
   The case was settled in 2017 under confidential terms, avoiding a cumulative court ruling.

4. Why do pharmaceutical companies pursue patent litigation?
   To protect market exclusivity, recoup R&D costs, and prevent competitors from launching similar products during patent life.

5. What lessons does this case impart for patent strategy?
   Securing strong, specific claims and preparing for validity challenges are crucial; early settlement can mitigate long-term litigation costs.

---

Key Takeaways

• Patent robustness matters: The scope and claims of the patent significantly influence litigation outcomes.
• Settlement is common: Many pharmaceutical patent litigations resolve through confidentiality agreements, prioritizing business continuity.
• Prior art challenges remain potent: Obviousness and anticipation arguments threaten patent validity and can lead to settlements or invalidation.
• Enforcement vs. validity battles: Companies often balance enforcement efforts with validity defenses to maximize market protection.
• Industry implications: Patents on formulations are critical assets, and their protection involves complex legal and technical strategies.

---

References

[1] U.S. Patent No. 8,568,150. "Topical compositions with improved absorption and stability," issued September 24, 2013.